Sitagliptin/simvastatin

< Sitagliptin
Sitagliptin/simvastatin
Combination of
Sitagliptinantidiabetic DPP-4 inhibitor
Simvastatinhypolipidemic statin
Clinical data
Trade namesJuvisync
AHFS/Drugs.comConsumer Drug Information
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
KEGG
 NY (what is this?)  (verify)

Sitagliptin/simvastatin, sold under the brand name Juvisync, is a fixed-dose combination anti-diabetic medication used to treat type 2 diabetes and hypercholesterolemia. It contains sitagliptin and simvastatin. Sitagliptin is a dipeptidyl peptidase-4 inhibitor and simvastatin is an HMG-CoA reductase inhibitor. These two disorders commonly occur in people at the same time, and have been typically treated with administration of these medications separately. The combination was approved in 2011, and sold under the brand name Juvisync by Merck. Juvisync was later removed from the market in 2013, due to business reasons.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.